Oscient To Pursue Factive Sinusitis Claim Despite FDA Refusal To File
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Oscient will pursue potential paths to file its antibiotic Factive for a supplemental indication to treat acute bacterial sinusitis after FDA refused to review its initial sNDA